News Novartis edges ahead in CAR-T race Novartis has filed its CAR-T cell therapy with the FDA, giving it an edge over Kite Pharma and its rival treatment.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News Kite and Fosun appoint leader for CAR-T debut in China But rival Juno finally gives up on lead therapy.
Views & Analysis Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T... Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
News Kite’s CAR-T therapy most valuable pipeline orphan drug Drug tops list compiled by Evaluate Pharma
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
